U-Neuron Biomedical Inc(TW:6973)
NT$54.89+0.10 (+0.18%)
TW:6973
U-Neuron Biomedical Inc financials statements
NT$54.89
At close:+0.10 (+0.18%)
U-Neuron Biomedical Inc (6973) Ratios
U-Neuron Biomedical Inc Ratios
TW:6973's free cash flow for Q2 2026 was NT$-37.56M. For the 2026 fiscal year, TW:6973's free cash flow was decreased by NT$-5.55M and operating cash flow was NT$-32.01M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 16.48 | 22.44 | 19.09 | 7.71 | 13.14 |
| Quick Ratio | 16.20 | 22.12 | 18.74 | 7.38 | 12.80 |
| Cash Ratio | 10.35 | 3.41 | 2.22 | 1.38 | 3.58 |
| Solvency Ratio | -0.78 | -1.47 | -2.50 | -1.59 | -0.60 |
| Operating Cash Flow Ratio | -1.06 | -1.56 | -2.07 | -1.61 | -0.04 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 592.17M | NT$ 739.49M | NT$ 458.66M | NT$ 150.73M | NT$ 187.68M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.01 | 0.02 | 0.02 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.01 | 0.02 | 0.03 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.01 | 0.02 | 0.03 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.07 | 1.04 | 1.06 | 1.14 | 1.08 |
| Debt Service Coverage Ratio | -80.55 | -196.38 | -1415.87 | -335.12 | 0.00 |
| Interest Coverage Ratio | -103.63 | -263.21 | -1642.20 | -400.70 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.42 | 0.17 | 0.37 | 0.28 | 0.00 |
| Net Debt to EBITDA | 7.68 | 2.19 | 0.61 | 0.73 | 5.77 |
| Profitability Margins | |||||
| Gross Profit Margin | 67.00% | 82.08% | 79.78% | 80.56% | 84.21% |
| EBIT Margin | -78.85% | -129.21% | -313.94% | -160.75% | -39.62% |
| EBITDA Margin | -61.29% | -111.35% | -288.17% | -136.35% | -33.84% |
| Operating Profit Margin | -78.85% | -149.23% | -334.24% | -163.04% | -53.02% |
| Pretax Profit Margin | -66.89% | -129.77% | -314.14% | -161.15% | -39.62% |
| Net Profit Margin | -66.89% | -129.77% | -314.14% | -161.15% | -39.62% |
| Continuous Operations Profit Margin | -66.89% | -129.77% | -314.14% | -161.15% | -39.62% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 84.83% | 86.96% | 93.99% | 98.84% | 74.72% |
| Return on Assets (ROA) | -7.24% | -7.08% | -16.23% | -23.17% | -5.33% |
| Return on Equity (ROE) | -7.78% | -7.39% | -17.26% | -26.44% | -5.76% |
| Return on Capital Employed (ROCE) | -9.00% | -8.49% | -18.15% | -26.67% | -7.69% |
| Return on Invested Capital (ROIC) | -8.96% | -8.44% | -17.98% | -25.97% | -7.69% |
| Return on Tangible Assets | -7.26% | -7.09% | -16.27% | -23.43% | -5.43% |
| Earnings Yield | -3.75% | -4.85% | -5.33% | -5.87% | -2.15% |
| Efficiency Ratios | |||||
| Receivables Turnover | 10.38 | 7.36 | 11.36 | 12.69 | 20.59 |
| Payables Turnover | 19.97 | 4.03 | 2.34 | 2.01 | 6.42 |
| Inventory Turnover | 2.47 | 0.75 | 0.62 | 0.69 | 0.86 |
| Fixed Asset Turnover | 0.79 | 0.88 | 1.79 | 3.07 | 12.23 |
| Asset Turnover | 0.11 | 0.05 | 0.05 | 0.14 | 0.13 |
| Working Capital Turnover Ratio | 0.12 | 0.08 | 0.09 | 0.16 | 0.23 |
| Cash Conversion Cycle | 164.70 | 448.22 | 465.82 | 374.42 | 383.13 |
| Days of Sales Outstanding | 35.16 | 49.60 | 32.13 | 28.76 | 17.73 |
| Days of Inventory Outstanding | 147.82 | 489.15 | 589.36 | 527.49 | 422.28 |
| Days of Payables Outstanding | 18.28 | 90.52 | 155.67 | 181.83 | 56.87 |
| Operating Cycle | 182.98 | 538.75 | 621.49 | 556.26 | 440.01 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.06 | -1.82 | -2.01 | -2.27 | -0.06 |
| Free Cash Flow Per Share | -2.20 | -3.34 | -2.10 | -2.49 | -0.22 |
| Dividend Paid and CapEx Coverage Ratio | -0.94 | -1.20 | -22.23 | -10.69 | -0.35 |
| Capital Expenditure Coverage Ratio | -0.94 | -1.20 | -22.23 | -10.69 | -0.35 |
| Operating Cash Flow Coverage Ratio | -2.62 | -11.01 | -5.51 | -8.26 | 0.00 |
| Operating Cash Flow to Sales Ratio | -0.50 | -1.17 | -1.97 | -1.36 | -0.02 |
| Free Cash Flow Yield | -5.80% | -7.99% | -3.49% | -5.40% | -0.48% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -26.69 | -23.78 | -18.75 | -17.04 | -46.46 |
| Price-to-Sales (P/S) Ratio | 17.85 | 26.76 | 58.95 | 27.46 | 18.41 |
| Price-to-Book (P/B) Ratio | 2.08 | 1.52 | 3.24 | 4.51 | 2.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -17.24 | -12.52 | -28.65 | -18.51 | -208.24 |
| Price-to-Operating Cash Flow Ratio | -35.68 | -22.94 | -29.94 | -20.24 | -801.07 |
| Price-to-Earnings Growth (PEG) Ratio | 1.38 | 0.53 | -0.99 | -0.10 | 0.00 |
| Enterprise Value Multiple | -21.45 | -21.84 | -19.85 | -19.41 | -48.63 |
| Enterprise Value | 1.09B | 1.12B | 1.55B | 709.15M | 467.58M |
| EV to EBITDA | -21.45 | -21.84 | -19.85 | -19.41 | -48.63 |
| EV to Sales | 13.15 | 24.32 | 57.20 | 26.47 | 16.45 |
| EV to Free Cash Flow | -12.70 | -11.38 | -27.80 | -17.84 | -186.14 |
| EV to Operating Cash Flow | -26.27 | -20.84 | -29.05 | -19.51 | -716.05 |
| Tangible Book Value Per Share | 18.20 | 27.43 | 18.54 | 10.08 | 17.06 |
| Shareholders’ Equity Per Share | 18.26 | 27.46 | 18.59 | 10.21 | 17.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 2.12 | 1.56 | 1.02 | 1.67 | 2.50 |
| Net Income Per Share | -1.42 | -2.03 | -3.21 | -2.70 | -0.99 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.85 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.92 | 1.69 | 2.86 | 1.75 | 0.93 |
| SG&A to Revenue | 0.54 | 0.63 | 1.28 | 0.69 | 0.44 |
| Stock-Based Compensation to Revenue | 0.00 | 0.03 | 0.93 | 0.00 | 0.01 |
| Income Quality | 0.75 | 0.90 | 0.63 | 0.84 | 0.06 |
Currency in TWD
